JP2023176003A5 - - Google Patents

Download PDF

Info

Publication number
JP2023176003A5
JP2023176003A5 JP2023176751A JP2023176751A JP2023176003A5 JP 2023176003 A5 JP2023176003 A5 JP 2023176003A5 JP 2023176751 A JP2023176751 A JP 2023176751A JP 2023176751 A JP2023176751 A JP 2023176751A JP 2023176003 A5 JP2023176003 A5 JP 2023176003A5
Authority
JP
Japan
Prior art keywords
kit
patient
virus
instructions
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023176751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023176003A (ja
Filing date
Publication date
Priority claimed from JP2018513549A external-priority patent/JP2018526428A/ja
Application filed filed Critical
Publication of JP2023176003A publication Critical patent/JP2023176003A/ja
Publication of JP2023176003A5 publication Critical patent/JP2023176003A5/ja
Pending legal-status Critical Current

Links

JP2023176751A 2015-09-09 2023-10-12 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 Pending JP2023176003A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562216046P 2015-09-09 2015-09-09
US201562216062P 2015-09-09 2015-09-09
US62/216,062 2015-09-09
US62/216,046 2015-09-09
US201562255294P 2015-11-13 2015-11-13
US62/255,294 2015-11-13
US201662323065P 2016-04-15 2016-04-15
US62/323,065 2016-04-15
JP2018513549A JP2018526428A (ja) 2015-09-09 2016-09-09 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2021147640A JP2022003043A (ja) 2015-09-09 2021-09-10 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021147640A Division JP2022003043A (ja) 2015-09-09 2021-09-10 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Publications (2)

Publication Number Publication Date
JP2023176003A JP2023176003A (ja) 2023-12-12
JP2023176003A5 true JP2023176003A5 (cg-RX-API-DMAC7.html) 2024-06-20

Family

ID=58240173

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018513549A Withdrawn JP2018526428A (ja) 2015-09-09 2016-09-09 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2021147640A Pending JP2022003043A (ja) 2015-09-09 2021-09-10 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2023176751A Pending JP2023176003A (ja) 2015-09-09 2023-10-12 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018513549A Withdrawn JP2018526428A (ja) 2015-09-09 2016-09-09 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2021147640A Pending JP2022003043A (ja) 2015-09-09 2021-09-10 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Country Status (4)

Country Link
US (3) US20190038727A1 (cg-RX-API-DMAC7.html)
EP (1) EP3347473A4 (cg-RX-API-DMAC7.html)
JP (3) JP2018526428A (cg-RX-API-DMAC7.html)
WO (1) WO2017044780A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
WO2017044780A1 (en) * 2015-09-09 2017-03-16 Tvax Biomedical I, Llc Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN117731763A (zh) * 2016-06-24 2024-03-22 麦克马斯特大学 过继细胞转移与溶瘤病毒组合疗法
CA3052463A1 (en) * 2017-02-03 2018-08-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
AU2019208892B2 (en) * 2018-01-19 2022-02-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
EP3897846A1 (en) * 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
US20220152168A1 (en) * 2019-03-20 2022-05-19 Children's Hospital Of Eastern Ontario Research Institute Inc. Sequential heterologous boost oncolytic viral immunotherapy
WO2020247547A1 (en) * 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof
WO2020247155A1 (en) * 2019-06-05 2020-12-10 Laitram, L.L.C. Self-stacking spiral belt conveyor with smooth diameter reduction
CN110540960A (zh) * 2019-09-11 2019-12-06 苏州大学 结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用
CN116802278A (zh) * 2020-09-18 2023-09-22 成都美杰赛尔生物科技有限公司 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤
EP4052716A1 (en) * 2021-03-04 2022-09-07 Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg Cancer therapy involving car-engineered t-cells and parvovirus h-1
WO2024054293A1 (en) * 2022-09-08 2024-03-14 Research Institute At Nationwide Children's Hospital Oncolytic virus combination to maximize oncolytic activity
WO2024124190A1 (en) 2022-12-09 2024-06-13 Microbial Machines, Inc. Engineered microorganisms for delivery of therapeutic agents
WO2024259195A1 (en) * 2023-06-16 2024-12-19 Elias Animal Health Use of cd200ar-l for enhancing adoptive t-cell therapy
WO2024263805A1 (en) 2023-06-21 2024-12-26 Microbial Machines, Inc. Genetically engineered microorganisms for detection of diseased cells
CN118045162A (zh) * 2024-02-28 2024-05-17 北京景达生物科技有限公司 核心蛋白聚糖联合nk细胞在治疗实体瘤中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2406387A4 (en) 2009-03-09 2013-04-17 Tvax Biomedical I Llc CELL IMMUNOTHERAPY FOR INFECTION DISEASES
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP3461491B1 (en) 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2017044780A1 (en) * 2015-09-09 2017-03-16 Tvax Biomedical I, Llc Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy

Similar Documents

Publication Publication Date Title
JP2018526428A5 (cg-RX-API-DMAC7.html)
Schirrmacher et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
Castro et al. DNA vaccination against a fish rhabdovirus promotes an early chemokine-related recruitment of B cells to the muscle
JP2022003043A (ja) 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
CN112384614B (zh) 表达干扰素的溶瘤病毒及其应用
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
JP2025023916A5 (cg-RX-API-DMAC7.html)
JP2011519869A5 (cg-RX-API-DMAC7.html)
CN104262459B (zh) 一种急性单核细胞白血病相关抗原mlaa‑34 表位多肽及其疫苗和制药应用
Flanagan et al. Production of macrophage migration inhibition factors by virus-infected cell cultures
Helmold et al. Advancing ORFV‐Based Therapeutics to the Clinical Stage
Verjan et al. A soluble nonglycosylated recombinant infectious hematopoietic necrosis virus (IHNV) G-protein induces IFNs in rainbow trout (Oncorhynchus mykiss)
CN113613672A (zh) 用于治疗胰腺癌的药物组合物
CN119768512A (zh) 突变的流感病毒、药物组合物及用途
Zheng et al. Immune response of DNA vaccine against lymphocystis disease virus and expression analysis of immune‐related genes after vaccination
CN106310250A (zh) 一种猪瘟口服弱毒冻干疫苗、其制备方法及冻干保护剂
Brenan et al. Influence of one virus infection on a second concurrent primary in vivo antiviral cytotoxic T-cell response
CN116785419B (zh) 二十三组分抗原非洲猪瘟亚单位疫苗
Al-Shamery et al. Immunology study for NDV treatment in mice bearing mammary adenocarcinoma tumor
US20190255127A1 (en) Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells
CN118956907A (zh) mRNA分子及其用途、传染性造血器官坏死病毒疫苗
Guo et al. Synergistic effects of oral inoculation with a recombinant Lactobacillus plantarum NC8 strain co-expressing interleukin-2 and interleukin-17B on the efficacy of the infectious bronchitis vaccine in chickens
JP2006096663A (ja) 癌遺伝子ワクチン
TWI386223B (zh) Duck hepatitis vaccine and its preparation method
CN1478896A (zh) 大肠杆菌表达甲胎蛋白的方法